Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-10-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于2025年度第一期定向科技创新债券发行结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance results of a directed technology innovation bond by the company 迈威（上海）生物科技股份有限公司. It details the bond issuance amount, interest rate, issuance date, and use of proceeds. There is no financial statement or comprehensive financial report included, only an issuance result announcement. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-10-16 Chinese
迈威生物自愿披露关于7MW3711在2025年欧洲肿瘤内科学会（ESMO）以海报形式报告数据及最新进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding clinical trial data and latest progress of their drug 7MW3711 presented in poster form at the 2025 European Society for Medical Oncology (ESMO) conference. It contains detailed clinical trial results, safety data, and risk warnings. The document is an announcement of clinical data presentation and progress update rather than a formal financial or regulatory report. It does not contain financial statements, audit information, or regulatory certifications. It is not a report publication announcement since it provides substantive data and analysis about the clinical trial progress. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical progress and risk disclosure, which does not fit other specific categories like earnings, capital updates, or management changes.
2025-10-13 Chinese
迈威生物自愿披露关于注射用7MW4911临床试验申请获得国家药品监督管理局批准的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding the approval of a clinical trial application for an injection drug 7MW4911 by the National Medical Products Administration (China's drug regulatory authority). It contains detailed information about the drug, its clinical trial approval, and risk warnings for investors. The document is an official announcement about regulatory approval and clinical trial status, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it provides substantive information about the clinical trial approval itself. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-10-13 Chinese
迈威生物关于以集中竞价交易方式回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase program, detailing the number of shares repurchased, prices, amounts spent, and adjustments to the repurchase price limits. It references specific board meetings approving the repurchase plan and adjustments, and provides cumulative repurchase data. The document does not contain financial statements or comprehensive financial analysis but focuses on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2025-10-09 Chinese
迈威生物关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 second extraordinary general meeting of shareholders for a company, including meeting date, voting methods, agenda items, registration procedures, and an authorization proxy form. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The content matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides information and requests votes for meetings. The document length is about 3,084 characters, consistent with a detailed meeting notice rather than a full report or voting results announcement.
2025-10-08 Chinese
迈威生物关于变更经营范围、修订《公司章程》并办理工商变更登记的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from the board of directors of 迈威（上海）生物科技股份有限公司 regarding changes to the company's business scope and amendments to the Articles of Association, as well as the process for handling industrial and commercial registration changes. It includes details of the proposed amendments and states that these changes require shareholder approval at a general meeting. The document is a formal announcement of corporate governance changes and procedural steps rather than a full report or financial statement. It does not contain financial data, audit information, or detailed management discussion. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes in company governance or management-related decisions.
2025-10-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.